BE
Beta Drugs Ltd (BETA)
₹1,996.50
Mkt cap
₹2,278 Cr
P/E ratio
50.00
P/B
8.28
Div yield
0.00%
ROE
18.80%
ROCE
19.20%
EPS (TTM)
₹39.93
Book value
₹241
52W range
990–2,808
Sector
Healthcare
Price history
Previous close
Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. It has operations in the domestic and export markets. [1]
NSE BETA
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
−28.90% from high₹1,997
₹990+101.65% from low₹2,808
Current
₹1,996.50
Prev close
₹2,020.00
Day
−1.16%
Price performance
1D
−1.16%
1W
−2.15%
1M
−11.62%
3M
−3.51%
6M
+43.92%
1Y
+10.18%
YTD
+22.53%
Financials
Revenue, profit & margin
P/E ratio
50.0×
BETA is 45% above the sector median of 34.6×
BETA50.0×
Sector median34.6×
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|
| Sales | 88 | 94 | 100 | 103 | 87 | 94 | 126 | |
| Expenses | 70 | 76 | 81 | 82 | 70 | 76 | 98 | |
| Operating Profit | 18 | 17 | 20 | 21 | 17 | 18 | 27 | |
| OPM % | 21% | 18% | 20% | 21% | 19% | 19% | 22% | |
| Other Income | -1 | 2 | 3 | 3 | 2 | 3 | 2 | |
| Interest | 2 | 3 | 3 | 4 | 4 | 4 | 3 | |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 5 | 4 | |
| Profit before tax | 12 | 12 | 16 | 16 | 10 | 12 | 22 | |
| Tax % | 25% | 26% | 25% | 26% | 19% | 24% | 25% | |
| Net Profit | 9 | 9 | 12 | 12 | 9 | 9 | 16 | |
| EPS in Rs | 8.86 | 8.95 | 11.59 | 12.11 | 8.40 | 8.93 | 14.25 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202659.10%Promoter
Promoters59.10%5.53
FIIs1.02%0.14
DIIs6.23%4.08
Public33.65%1.59
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Beta Drugs Ltd | ₹2,055.20 | 49.98 | 2,278 | 0.00% | 16 | +35.04% | 126 | +25.29% | 19.16% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports9
Concall transcripts26
PPTJul 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptNov 2024PPTNov 2024TranscriptMay 2024PPTMay 2024TranscriptNov 2023PPTNov 2023TranscriptMay 2023PPTMay 2023TranscriptNov 2022PPTNov 2022TranscriptMay 2022PPTMay 2022TranscriptDec 2021PPTDec 2021
Credit ratings6
Announcements5
Analysts/Institutional Investor Meet/Con. Call Updates 10 Sep - Beta Drugs will join Valorem CXO virtual meet on 17 September 2026 at 4:00 pm IST.Copy of Newspaper Publication 7 Sep - Beta Drugs published newspaper notice for 21st AGM on 30 September 2026.Shareholders meeting 5 Sep - Beta Drugs schedules 21st AGM on 30 Sep 2026; seeks auditor reappointment and Ashutosh Shukla's reappointment.General Updates 3 Sep - Book closure from 24–30 September 2026 for Beta Drugs' 21st AGM on 30 September 2026.Shareholders meeting 3 Sep - Beta Drugs’ 21st AGM will be held on 30 September 2026 at its Baddi registered office.